---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-24-011633"
form_type: "8-K"
ticker: "NUWE"
cik: "0001506492"
company_name: "Nuwellis, Inc."
filed_at: "2024-03-06T23:59:59+00:00"
generated_at: "2026-06-05T02:35:20.586610+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Nuwellis Q4 revenue record $2.6M (+9% YoY); net loss $7.9M on financing costs; pediatric sales up 35%

## Summary
- Q4 revenue $2.6M (+9% YoY); full year revenue $8.9M (+4% YoY).
- Net loss attributable to common $7.9M ($2.24/share) includes $4.4M financing-related charges; prior year net loss $1.9M.
- Pediatric revenue +35% YoY in Q4; utilization +28%, console sales +49%, 4 new accounts added.
- Cash $3.8M, no debt; CEO targets 40% cash-burn reduction and expects capital raise in 2024.
- New products launched: 12cm dELC catheter, Quelimmune pediatric device; IDE submission for Vivian device planned.

## SEC filing metadata
- accession: 0001140361-24-011633
- form_type: 8-K
- ticker: NUWE
- cik: 0001506492
- company_name: Nuwellis, Inc.
- filed_at: 2024-03-06T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1506492/000114036124011633/0001140361-24-011633-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1506492/000114036124011633/ef20023378_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-24-011633
- JSON: https://secwatch.observer/filing/0001140361-24-011633.json
- Plain text: https://secwatch.observer/filing/0001140361-24-011633.txt

## Key facts
- Earnings Releases
  Nuwellis, Inc. reported fourth quarter and full year ended December 31, 2023 results: revenue $2.6 million, net income net loss attributable to common shareholders of $7.9 million, EPS loss of $2.24 per basic and diluted common share.
  - Period: fourth quarter and full year ended December 31, 2023
  - Revenue: $2.6 million
  - Net income: net loss attributable to common shareholders of $7.9 million
  - EPS: loss of $2.24 per basic and diluted common share
  - Result: reported results
  source text: the lives of people with fluid overload, today reported financial results for the fourth quarter and full year ended December 31, 2023. Highlights: ● Record quarter revenue of $2.6 million, a 9% increase over prior-year period. Full year revenue of $8.9 million, a 4% increase over 2022. ● Fourth quarter pediatric revenue grew 35% year over year; 28% increase in
  evidence_url: https://www.sec.gov/Archives/edgar/data/1506492/000114036124011633/0001140361-24-011633-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.